Loading clinical trials...
Loading clinical trials...
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer. The main question it aims to answer are: * Which diagnostic modality is preferred by patients and the general population? * Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality? * Are geographical differences present in regard to the preference for a diagnostic modality? Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
Yes
University Hospitals Leuven
Leuven, Belgium
Start Date
August 1, 2024
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2026
Last Updated
February 18, 2026
2,200
ESTIMATED participants
Survey
OTHER
Lead Sponsor
KU Leuven
NCT04704661
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions